References
- Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25. https://doi.org/https://doi.org/10.1016/j.softx.2015.06.001
- Ahmad, S., Bhagwati, S., Kumar, S., Banerjee, D., & Siddiqi, M. I. (2020). Molecular modeling assisted identification and biological evaluation of potent cathepsin S inhibitors. Journal of Molecular Graphics and Modelling, 96, 107512. https://doi.org/https://doi.org/10.1016/j.jmgm.2019.107512
- Al-Nadaf, A. H., & Taha, M. O. (2011). Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation. Journal of Molecular Graphics & Modelling, 29(6), 843–864. https://doi.org/https://doi.org/10.1016/j.jmgm.2011.02.001
- Berman, H. M., Bourne, P. E., Westbrook, J., & Zardecki, C. (2003). The protein data bank. In Protein structure (pp. 394–410). CRC Press.
- Bhagwati, S., & Siddiqi, M. I. (2020). Identification of potential soluble epoxide hydrolase (sEH) inhibitors by ligand-based pharmacophore model and biological evaluation. Journal of Biomolecular Structure & Dynamics, 38(16), 4956–4966. https://doi.org/https://doi.org/10.1080/07391102.2019.1691659
- Boughorbel, S., Jarray, F., & El-Anbari, M. (2017). Optimal classifier for imbalanced data using Matthews correlation coefficient metric. PloS One, 12(6), e0177678. https://doi.org/https://doi.org/10.1371/journal.pone.0177678
- Brown, M. J. (2006). Direct renin inhibition - a new way of targeting the renin system. Journal of the Renin Angiotensin Aldosterone System, 7, S7. https://doi.org/https://doi.org/10.3317/jraas.2006.035
- Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250. https://doi.org/https://doi.org/10.1016/j.drudis.2018.01.039
- Chen, Y., Meng, G., Bai, W., Ma, Y., Xie, L., Altaf, N., Qian, Y., Han, Y., & Ji, Y. (2017). Aliskiren protects against myocardial ischaemia-reperfusion injury via an endothelial nitric oxide synthase dependent manner. Clinical and Experimental Pharmacology & Physiology, 44(2), 266–274. https://doi.org/https://doi.org/10.1111/1440-1681.12692
- Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019). Exploiting machine learning for end-to-end drug discovery and development. Nature Materials, 18(5), 435–441. https://doi.org/https://doi.org/10.1038/s41563-019-0338-z
- Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49(21), 6177–6196. https://doi.org/https://doi.org/10.1021/jm051256o
- Fu, S., Wen, X., Han, F., Long, Y., & Xu, G. (2017). Aliskiren therapy in hypertension and cardiovascular disease: A systematic review and a meta-analysis. Oncotarget, 8(51), 89364–89374. https://doi.org/https://doi.org/10.18632/oncotarget.19382
- Gasparo, M. D., Speth, R. C., Baltatu, O. C., & Vanderheyden, P. (2013). Brain RAS: Hypertension and beyond. International Journal of Hypertension, 2013, 157180. https://doi.org/https://doi.org/10.1155/2013/157180
- Gheorghiade, M., Böhm, M., Greene, S. J., Fonarow, G. C., Lewis, E. F., Zannad, F., Solomon, S. D., Baschiera, F., Botha, J., Hua, T. A., Gimpelewicz, C. R., Jaumont, X., Lesogor, A., Maggioni, A. P, & ASTRONAUT Investigators and Coordinators (2013). Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: The ASTRONAUT randomized trial. JAMA, 309(11), 1125–1135. https://doi.org/https://doi.org/10.1001/jama.2013.1954
- Gradman, A. H., Schmieder, R. E., Lins, R. L., Nussberger, J., Chiang, Y., & Bedigian, M. P. (2005). Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 111(8), 1012–1018. https://doi.org/https://doi.org/10.1161/01.CIR.0000156466.02908.ED
- Gross, F., Lazar, J., & Orth, H. (1972). Inhibition of the renin-angiotensinogen reaction by pepstatin. Science (New York, N.Y.), 175(4022), 656–656. https://doi.org/https://doi.org/10.1126/science.175.4022.656
- Hofbauer, K. G., & Wood, J. M. (1988). Renin inhibitors as possible antihypertensive agents. Klinische Wochenschrift, 66(18), 906–913. https://doi.org/https://doi.org/10.1007/BF01728953
- Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14(1), 33–38. https://doi.org/https://doi.org/10.1016/0263-7855(96)00018-5
- Jensen, C., Herold, P., & Brunner, H. R. (2008). Aliskiren: The first renin inhibitor for clinical treatment. Nature Reviews. Drug Discovery, 7(5), 399–410. https://doi.org/https://doi.org/10.1038/nrd2550
- Jiménez, J., Skalic, M., Martinez-Rosell, G., & De Fabritiis, G. (2018). KDEEP: Protein-ligand absolute binding affinity prediction via 3D-convolutional neural networks. Journal of Chemical Information and Modeling, 58(2), 287–296. https://doi.org/https://doi.org/10.1021/acs.jcim.7b00650
- John, S., Thangapandian, S., Arooj, M., Hong, J. C., Kim, K. D., & Lee, K. W. (2011). Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors. BMC Bioinformatics, 12(Suppl 14), S4. https://doi.org/https://doi.org/10.1186/1471-2105-12-S14-S4
- Kireev, D. (2016). Structure-based virtual screening of commercially available compound libraries. High throughput screening (pp. 65–76). Humana Press. https://doi.org/https://doi.org/10.1007/978-1-4939-3673-1_4
- LigPrep. (2018). Schrödinger, LLC, New York.
- Ma, T. K., Kam, K. K., Yan, B. P., & Lam, Y. Y. (2010). Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status. British Journal of Pharmacology, 160(6), 1273–1292. https://doi.org/https://doi.org/10.1111/j.1476-5381.2010.00750.x
- Morgan, H. L. (1965). The generation of a unique machine description for chemical structures - a technique developed at chemical abstracts service. Journal of Chemical Documentation, 5(2), 107–113. https://doi.org/https://doi.org/10.1021/c160017a018
- Musini, V. M., Lawrence, K. A., Fortin, P. M., Bassett, K., & Wright, J. M. (2017). Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews, (4). https://doi.org/https://doi.org/10.1002/14651858.CD007066.pub3
- Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012). Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking. Journal of Medicinal Chemistry, 55(14), 6582–6594. https://doi.org/https://doi.org/10.1021/jm300687e
- Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190. https://doi.org/https://doi.org/10.1063/1.328693
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A. (2012). Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine, 367(23), 2204–2213. https://doi.org/https://doi.org/10.1056/NEJMoa1208799
- Pool, J. L., Schmieder, R. E., Azizi, M., Aldigier, J. C., Januszewicz, A., Zidek, W., Chiang, Y., & Satlin, A. (2007). Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension, 20(1), 11–20. https://doi.org/https://doi.org/10.1016/j.amjhyper.2006.06.003
- Powers, D. M. (2011). Evaluation: From precision, recall and F-measure to ROC, informedness, markedness and correlation.
- Rahuel, J., Rasetti, V., Maibaum, J., Rüeger, H., Göschke, R., Cohen, N. C., Stutz, S., Cumin, F., Fuhrer, W., Wood, J. M., & Grütter, M. G. (2000). Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin. Chemistry & Biology, 7(7), 493–504. https://doi.org/https://doi.org/10.1016/S1074-5521(00)00134-4
- Rogers, D., & Hahn, M. (2010). Extended-connectivity fingerprints. Journal of Chemical Information and Modeling, 50(5), 742–754. https://doi.org/https://doi.org/10.1021/ci100050t
- Sagui, C., Pedersen, L. G., & Darden, T. A. (2004). Towards an accurate representation of electrostatics in classical force fields: Efficient implementation of multipolar interactions in biomolecular simulations. The Journal of Chemical Physics, 120(1), 73–87. https://doi.org/https://doi.org/10.1063/1.1630791
- Saito, T., & Rehmsmeier, M. (2015). The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets. PloS One, 10(3), e0118432. https://doi.org/https://doi.org/10.1371/journal.pone.0118432
- Shafiq, M. M., Menon, D. V., & Victor, R. G. (2008). Oral direct renin inhibition: Premise, promise, and potential limitations of a new antihypertensive drug. The American Journal of Medicine, 121(4), 265–271. https://doi.org/https://doi.org/10.1016/j.amjmed.2007.11.016
- Skeggs, L. T., Dorer, F. E., Kahn, J. R., Lentz, K. E., & Levine, M. (1976). The biochemistry of the renin-angiotensin system and its role in hypertension. The American Journal of Medicine, 60(6), 737–748. https://doi.org/https://doi.org/10.1016/0002-9343(76)90888-3
- Staessen, J. A., Li, Y., & Richart, T. (2006). Oral renin inhibitors. The Lancet, 368(9545), 1449–1456. https://doi.org/https://doi.org/10.1016/S0140-6736(06)69442-7
- Stanton, A. (2003). Potential of renin inhibition in cardiovascular disease. Journal of the Renin-Angiotensin-Aldosterone System: JRAAS, 4(1), 6–10. https://doi.org/https://doi.org/10.3317/jraas.2003.008
- Szelke, M., Leckie, B., Hallett, A., Jones, D. M., Sueiras, J., Atrash, B., & Lever, A. F. (1982). Potent new inhibitors of human renin. Nature, 299(5883), 555–557. https://doi.org/https://doi.org/10.1038/299555a0
- Thangapandian, S., John, S., Sakkiah, S., & Lee, K. W. (2011). Potential virtual lead identification in the discovery of renin inhibitors: Application of ligand and structure-based pharmacophore modeling approaches. European Journal of Medicinal Chemistry, 46(6), 2469–2476. https://doi.org/https://doi.org/10.1016/j.ejmech.2011.03.035
- Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews. Drug Discovery, 18(6), 463–477. https://doi.org/https://doi.org/10.1038/s41573-019-0024-5
- Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., & MacKerell Jr., A. D. (2010). CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of Computational Chemistry, 31(4), 671–690. https://doi.org/https://doi.org/10.1002/jcc.21367
- Webb, D. J., Manhem, P. J., Ball, S. G., Inglis, G., Leckie, B. J., Lever, A. F., Morton, J. J., Robertson, J. I., Murray, G. D., & Ménard, J. (1985). A study of the renin inhibitor H142 in man. Journal of Hypertension, 3(6), 653–658. https://doi.org/https://doi.org/10.1097/00004872-198512000-00013
- Wood, J. M., Gulati, N., Forgiarini, P., Fuhrer, W., & Hofbauer, K. G. (1985). Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension (Dallas, TX: 1979), 7(5), 797–803. https://doi.org/https://doi.org/10.1161/01.hyp.7.5.797
- Xie, X. Q. S. (2010). Exploiting PubChem for virtual screening. Expert Opinion on Drug Discovery, 5(12), 1205–1220. https://doi.org/https://doi.org/10.1517/17460441.2010.524924
- Yap, C. W. (2011). PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints. Journal of Computational Chemistry, 32(7), 1466–1474. https://doi.org/https://doi.org/10.1002/jcc.21707
- Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., Volkov, Y., Zholus, A., Shayakhmetov, R. R., Zhebrak, A., Minaeva, L. I., Zagribelnyy, B. A., Lee, L. H., Soll, R., Madge, D., Xing, L., … Aspuru-Guzik, A. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 37(9), 1038–1040. https://doi.org/https://doi.org/10.1038/s41587-019-0224-x
- Zoete, V., Cuendet, M. A., Grosdidier, A., & Michielin, O. (2011). SwissParam: A fast force field generation tool for small organic molecules. Journal of Computational Chemistry, 32(11), 2359–2368. https://doi.org/https://doi.org/10.1002/jcc.21816